血栓素A2与糖尿病心血管并发症

心血管疾病是现今导致病人发病和死亡的首要因素,很多因素在血管性疾病发病发展中起着重要作用,血栓形成是参与脑中风及急性冠状动脉综合症的首要因素。血栓素A2（TXA2）是一种强血小板活化因子,在糖尿病患者体内的合成显著增加,并通过作用于血栓素受体诱导血小板聚集,血管收缩,血栓形成参与糖尿病心血管并发症的发生发展。因此,以TXA2为靶点开发抗血栓类药物对心血管疾病起着预防及治疗作用。本文对TXA2介导的糖尿病血管并发症的发病机制,及以此为靶点开发的抗血栓药物进行综述,为糖尿病心血管并发症的治疗及新型低副作用抗血栓药物的研发提供新的靶点。

Thrombaxane A2 and Cardiovascular Complications of Diabetes

Cardiovascular diseases are one of the leading causes of morbidity and mortality in modem society, and although many processes play a role in the development of vascular disease, thrombosis is the primary event that precipitates stroke and acute coronary syndromes. Thromboxane A2 （TXA2）, is a strong platelet activator. In diabetic patients, the synthesis of TXA2 is increased. TXA2 plays a critical role in the initiation and development of cardiovascular complications, by bonding at TXA： receptor, and then inducing platelet aggregation, vascular smooth contraction and thrombosis. Consequently, it is of great interest to develop drugs toward the target of TXA2. The aim of this review is to clarify the mechanisms of TXA2 in the pathology of diabetic cardiovascular complications, and provide new targets to develop possibly novel drugs which exhibit low adverse effects in cardiovascular complications therapy.